Your browser doesn't support javascript.
Anti-spike protein antibody titer at the time of breakthrough infection of SARS-CoV-2 omicron.
Adachi, Eisuke; Nagai, Etsuko; Saito, Makoto; Isobe, Masamichi; Konuma, Takaaki; Koga, Michiko; Tsutsumi, Takeya; Nannya, Yasuhito; Yotsuyanagi, Hiroshi.
  • Adachi E; Department of Infectious Diseases and Applied Immunology, IMSUT Hospital of the Institute of Medical Science, The University of Tokyo, Tokyo, Japan. Electronic address: eadachi-ims@umin.ac.jp.
  • Nagai E; Department of Laboratory Medicine, IMSUT Hospital of the Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Saito M; Division of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
  • Isobe M; Department of Hematology/Oncology IMSUT Hospital of the Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Konuma T; Division of Hematopoietic Disease Control, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
  • Koga M; Division of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
  • Tsutsumi T; Division of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
  • Nannya Y; Department of Hematology/Oncology IMSUT Hospital of the Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Division of Hematopoietic Disease Control, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
  • Yotsuyanagi H; Department of Infectious Diseases and Applied Immunology, IMSUT Hospital of the Institute of Medical Science, The University of Tokyo, Tokyo, Japan; Division of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
J Infect Chemother ; 28(7): 1015-1017, 2022 Jul.
Article in English | MEDLINE | ID: covidwho-1768315
ABSTRACT
By December 2021, about 80% of people over the age of 12 had been vaccinated in Japan, and almost all people were vaccinated with the mRNA vaccine. We investigated here the anti-spike protein antibody titer at the time of breakthrough infection of SARS-CoV-2 omicron. A total of 32 SARS-CoV2 omicron breakthrough infection was included in the study. The median antibody titer at breakthrough infection was 776 AU/mL overall, of which the median antibody titer of BNT162b2 vaccinated was 633 AU/mL and that of mRNA-1273 vaccinated was 9416 AU/mL. This result suggests that low levels of antibody titers 6 months after vaccination do not provide sufficient antibodies to prevent the omicron variant breakthrough infection, which may occur with a higher anti-spike antibody titer after vaccination with mRNA-1273. However, antibody titers in some patients were comparable to those immediately after the second vaccination with either mRNA vaccine.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Topics: Vaccines / Variants Limits: Humans Language: English Journal: J Infect Chemother Journal subject: Microbiology / Drug Therapy Year: 2022 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Topics: Vaccines / Variants Limits: Humans Language: English Journal: J Infect Chemother Journal subject: Microbiology / Drug Therapy Year: 2022 Document Type: Article